you are here: Home News Syngene

Syngene

Sai Life Sciences: Getting positioned for complex offerings
Syngene: Is the worst of worries priced in?
What does the new US Biosecure draft Act mean for the Indian CRDMO industry?
Sai Life Sciences: Strong start keeps CDMO business in the lead
Syngene: How soon can it overcome near-term worries?
Syngene: Growth trajectory to moderate in FY26
Syngene: US acquisition underlines welcome tweak in business model
Syngene acquires first manufacturing site in US
Syngene: Conversion of pilot projects to long-term contracts a big positive
Syngene shares slide over 4% on guidance cut as demand revival looks delayed
Sai Life Sciences: Differentiated CRDMO business model to help during Trump 2.0
What’s the importance of US Biosecure Act for India?
Syngene: Strong play on ‘China Switches’ in the CRAMS space
Syngene: The preferred pick for sector re-allocation
Weekly Tactical Pick: China+1 trend to enhance earnings visibility for this CRAMS player
High single digit to low double digits revenue projections for FY 25: Syngene CEO
Syngene International March quarter net profit up 6% to Rs 189 crore, revenue down 8%
UBS downgrades Syngene to ‘sell’ on weak outlook, shares slip 3%
Syngene: Preferred CRAMS play for the long term
Syngene: Stock correction serves as an opportunity to move in
Syngene: Inorganic initiative to speed up biologics manufacturing bandwidth
Syngene: Zoetis opportunity unfolds
Syngene: Timeline for follow-through in Zoetis contract key catalyst to watch
Syngene: Can it keep its premium valuation, going forward?
Moneycontrol Selects: Top stories this evening

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Syngene

Sai Life Sciences: Getting positioned for complex offerings

Syngene: Is the worst of worries priced in?

What does the new US Biosecure draft Act mean for the Indian CRDMO industry?

Sai Life Sciences: Strong start keeps CDMO business in the lead

Syngene: How soon can it overcome near-term worries?

Syngene: Growth trajectory to moderate in FY26

Syngene: US acquisition underlines welcome tweak in business model

Syngene acquires first manufacturing site in US

Syngene: Conversion of pilot projects to long-term contracts a big positive

Syngene shares slide over 4% on guidance cut as demand revival looks delayed

Sai Life Sciences: Differentiated CRDMO business model to help during Trump 2.0

What’s the importance of US Biosecure Act for India?

Syngene: Strong play on ‘China Switches’ in the CRAMS space

Syngene: The preferred pick for sector re-allocation

Weekly Tactical Pick: China+1 trend to enhance earnings visibility for this CRAMS player

High single digit to low double digits revenue projections for FY 25: Syngene CEO

Syngene International March quarter net profit up 6% to Rs 189 crore, revenue down 8%

UBS downgrades Syngene to ‘sell’ on weak outlook, shares slip 3%

Syngene: Preferred CRAMS play for the long term

Syngene: Stock correction serves as an opportunity to move in

Syngene: Inorganic initiative to speed up biologics manufacturing bandwidth

Syngene: Zoetis opportunity unfolds

Syngene: Timeline for follow-through in Zoetis contract key catalyst to watch

Syngene: Can it keep its premium valuation, going forward?

Moneycontrol Selects: Top stories this evening